June 06, 2023
Executives of biopharmaceutical company Fate Therapeutics Inc. have been hit with a shareholder derivative suit alleging they misled investors about the feasibility of a $50 million collaboration agreement with a Johnson & Johnson unit, leading to a stock price decline when the agreement was later terminated.